When Feng Zhang's lab first reported Cas12a — then called Cpf1 — in Cell in 2015, the message was clear: Cas9 was not the only game in town. Cas12a is smaller, needs only a single RNA, recognizes a different PAM, and leaves staggered "sticky-end" cuts instead of blunt ones. A decade later, the broader Cas12 family has spawned editing platforms, the most sensitive nucleic acid diagnostics ever built, and a whole class of "miniature" CRISPR enzymes that fit into delivery vehicles where Cas9 simply does not.
This article focuses on Cas12a / Cpf1 as the canonical example, then surveys the rapidly expanding Cas12 family — Cas12b, Cas12f, CasMINI, and CasX — and explains why size and PAM preference make these enzymes indispensable for modern gene editing.
What Are Cas12 and Cas12a?
Cas12a was discovered by Bernd Zetsche, Jonathan Strecker, Feng Zhang, and colleagues, reported in Cell in October 2015 ("Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System"). The enzyme was originally named Cpf1 (CRISPR from Prevotella and Francisella 1) and later renamed Cas12a to fit the unified CRISPR nomenclature established by the Koonin–Makarova classification.
Cas12 enzymes belong to Class 2, Type V CRISPR systems — distinct from the Class 2, Type II Cas9 family. They share the basic logic of an RNA-guided DNA endonuclease, but differ in almost every mechanical detail.
How Cas12a Works at the Molecular Level
Five features distinguish Cas12a from Cas9:
1. Single RNA, no tracrRNA. Cas9 requires both a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA), usually fused into one synthetic guide RNA. Cas12a uses a single crRNA — no tracrRNA needed. This simplifies guide design and reduces synthesis cost.
2. T-rich PAM (TTTV). Cas9 prefers a G-rich NGG PAM. Cas12a recognizes TTTV (where V = A, C, or G) at the 5′ end of the protospacer. This makes Cas12a uniquely useful for editing AT-rich regions of the genome — including many plant and parasite genomes — where Cas9 PAMs are scarce.
3. Staggered cuts. Cas12a cleaves DNA distal to the PAM, producing a 4–5 nucleotide 5′ overhang ("sticky end") rather than Cas9's blunt break. Sticky ends bias repair toward homology-directed repair and may improve knock-in efficiency.
4. Single nuclease domain (RuvC). Cas9 uses two nuclease domains (HNH for the target strand, RuvC for the non-target strand). Cas12a uses only RuvC, which sequentially cleaves both strands. This is why D917A or E1006A mutations can convert Cas12a into a nickase or dCas12a.
5. Collateral cleavage. After Cas12a is activated by binding its target dsDNA, it begins indiscriminately chewing up any single-stranded DNA in the vicinity. This trans-cleavage activity is a problem for editing but a gift to diagnostics — it is the basis of the DETECTR platform.
Key Papers and Milestones
- Zetsche et al., 2015 (Cell). Discovery of Cpf1/Cas12a.
- Chen et al., 2018 (Science). Doudna lab — DETECTR diagnostic platform exploiting Cas12a collateral cleavage.
- Strecker et al., 2019 (Science). Cas12b engineered for human-cell editing.
- Karvelis et al., 2020 (Nature). Cas12f (Cas14) — among the smallest CRISPR nucleases known, ~400–700 amino acids.
- Xu et al., 2021 (Molecular Cell). CasMINI — engineered miniature Cas12f from Stanley Qi's lab, only ~529 amino acids, capable of robust human-cell editing.
- Liu et al., 2019 (Nature). CasX (now Cas12e) from the Doudna lab — discovered in groundwater bacteria, ~980 amino acids.
- Broughton et al., 2020 (Nature Biotechnology). SARS-CoV-2 detection with DETECTR.
Applications and Use Cases
Therapeutic genome editing. Cas12a's small size and sticky-end cuts make it attractive for clinical editing. Editas Medicine has used a Cas12a-based editor (AsCas12a Ultra) in their EDIT-301 program for sickle cell disease — the same indication targeted by Casgevy. (See Casgevy: A Milestone in Gene Therapy.)
AAV delivery. Smaller enzymes fit better into AAV's ~4.7 kb cargo limit. CasX, Cas12f, and CasMINI all squeeze into a single AAV with room for a guide RNA and a tissue-specific promoter — something SpCas9 cannot do.
Agriculture. Calyxt (now Cibus) and Inari Agriculture use Cas12a for crop editing, exploiting its TTTV PAM to access AT-rich plant genomes that Cas9 struggles with.
Diagnostics — SHERLOCK and DETECTR. Cas12a's collateral cleavage activity, combined with isothermal amplification, produces a molecular detector sensitive to single nucleic acid molecules. SHERLOCK (Cas13-based, see our Cas13 article) and DETECTR (Cas12-based) were both deployed for COVID-19 testing and won FDA emergency use authorization in 2020.
Multiplexed editing. Because Cas12a processes its own crRNA arrays, a single transcript can encode multiple guides. This makes Cas12a uniquely good at editing several loci at once.
Cas12a vs Cas9
| Feature | Cas12a (Cpf1) | SpCas9 |
|---|---|---|
| Size | ~1,300 aa | ~1,368 aa |
| Guide RNA | Single crRNA, no tracrRNA | crRNA + tracrRNA (sgRNA fusion) |
| PAM | 5′ TTTV | 3′ NGG |
| Cut type | Staggered (sticky end) | Blunt |
| Nuclease domains | RuvC only | HNH + RuvC |
| Collateral cleavage | Yes (ssDNA) | No |
| Multiplexing | Native (array processing) | Requires multiple sgRNA cassettes |
The Broader Cas12 Family
- Cas12b (C2c1). Discovered by the Zhang lab. ~1,100 aa. Thermostable variants enable in vitro applications.
- Cas12e (CasX). ~980 aa. Discovered in 2019 by the Doudna lab in groundwater metagenomes.
- Cas12f (Cas14). ~400–700 aa. Among the smallest known CRISPR nucleases.
- CasMINI. ~529 aa. Engineered Cas12f variant from the Qi lab, optimized for mammalian editing.
- Cas12j (CasΦ). ~750 aa. Discovered in huge bacteriophages.
The trend is unmistakable: smaller is better when delivery is the bottleneck. Scribe Therapeutics, co-founded by Jennifer Doudna, is building therapeutic editors around CasX. Mammoth Biosciences, also co-founded by Doudna, uses Cas12 and Cas14 enzymes for both diagnostics and editing.
Connection to the Broader Gene Editing Ecosystem
Cas12a and its relatives are foundational alternatives to the SpCas9 chassis behind most CRISPR and Casgevy-style therapies. Their small size makes them especially relevant to delivery system constraints, and their distinct PAM preferences expand the reachable genome. The collateral cleavage activity that Cas12 and Cas13 share is the basis for an entire diagnostics industry — see our companion Cas13 RNA targeting article. And like all DNA-cutting nucleases, Cas12a editors have to grapple with the off-target challenges that plague the field, though their staggered cuts and longer guides may give them a small advantage. Feng Zhang's role in discovering and engineering Cas12a is part of his broader contribution covered in his profile.
Current Limitations and Challenges
- Activity in mammalian cells. Wild-type Cas12a is less efficient than Cas9 in human cells. Engineered variants (AsCas12a Ultra, enAsCas12a) close the gap but at the cost of higher off-target activity.
- PAM constraints. TTTV is rare in some genomic regions, just as NGG is rare in others.
- Temperature sensitivity. Some Cas12 enzymes lose activity at 37 °C, limiting therapeutic use.
- Collateral activity. While useful for diagnostics, trans-ssDNA cleavage in cells is a poorly characterized risk.
- Patent landscape. Cas12a IP overlaps with the broader CRISPR patent disputes.
FAQ
What is the difference between Cas12a and Cpf1?
None. Cpf1 was the original name from Zetsche et al. 2015. The CRISPR community later renamed it Cas12a under the unified Class 2 / Type V nomenclature.
Why does Cas12a need only one RNA?
Cas12a's crRNA folds into a structure that performs both target recognition and the scaffolding role that tracrRNA provides in Cas9. This was a major surprise of the 2015 paper.
Is Cas12a more accurate than Cas9?
On average, yes — engineered Cas12a variants tend to show fewer off-targets than wild-type Cas9, partly because their longer 23 nt protospacer demands a tighter match.
What is CasMINI?
An engineered miniature Cas12f variant from Stanley Qi's lab (Xu et al. 2021), ~529 amino acids — small enough to enable single-AAV delivery with room to spare.
Is Cas12a in clinical trials?
Yes. Editas Medicine's sickle cell program EDIT-301 uses an AsCas12a Ultra editor and has reported promising clinical data.
What is the relationship between Cas12 and Cas13?
Both are Class 2 CRISPR systems. Cas12 cuts DNA. Cas13 cuts RNA. Both display collateral cleavage that powers diagnostics.
